Our study also demonstrates that subtypes of glioma have a high IDH mutation frequency and that these are known to improve survival and exhibit similar traits; however, different effects can be derived from the same gene, and this would result in survival differences in different subtypes such as ODs and astrocytomas. This evidence concerns the gene IDH2 and central nervous system cancer.